Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...

Luana R. C. Pesco Koplowitz, M.D., Ph.D., Founder, President and Chief Scientific Officer of DUCK FLATS Pharma commented, “It is rewarding to engage with Oragenics on overall development strategy for ...

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a ...

Neuren shares FDA feedback on NNZ-2591 development plans in HIE and PTHS, with next steps and management insights. The post ...

By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Fully Focused on Rapid Advancement of ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics ...

Many times, when people think about joining clinical trials, getting a doctor’s referral is the first thing that comes to ...

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to treat overactive bladder symptoms, reduces hot flashes compared to the ...

Boutique MedTech CRO gains access to unified eClinical platform with wholesale pricing, training, and joint marketing ...

In recent days, Allogene Therapeutics reported encouraging clinical trial outcomes and new FDA designations for its off‑the‑shelf CAR T‑cell therapies, while analysts cited a supportive sector ...

AMT-191 has been granted both Orphan Drug and Fast Track designation by the U.S. Food and Drug Administration.

Conference: Piper Sandler Virtual Novel Targets in Immunology Symposium Format: Fireside chat Presenters: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer, Andrew R. Neill, Chief Financial ...